{"id":"NCT04335591","sponsor":"Kissei Pharmaceutical Co., Ltd.","briefTitle":"Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6)","officialTitle":"A Double-blind Randomized Extension Study to Assess the Long-term Efficacy and Safety of Linzagolix in Subjects With Endometriosis-associated Pain","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-03-05","primaryCompletion":"2022-09-15","completion":"2022-12-15","firstPosted":"2020-04-06","resultsPosted":"2024-04-30","lastUpdate":"2025-04-02"},"enrollment":356,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Endometriosis"],"interventions":[{"type":"DRUG","name":"75 mg linzagolix tablet","otherNames":[]},{"type":"DRUG","name":"200 mg linzagolix tablet","otherNames":[]},{"type":"DRUG","name":"Placebo tablet to match 75 mg linzagolix tablet","otherNames":[]},{"type":"DRUG","name":"Placebo tablet to match 200 mg linzagolix tablet","otherNames":[]},{"type":"DRUG","name":"Add-back capsule (E2 1 mg / NETA 0.5 mg)","otherNames":[]},{"type":"DRUG","name":"Placebo capsule to match Add-back capsule","otherNames":[]}],"arms":[{"label":"Linzagolix 75 mg","type":"EXPERIMENTAL"},{"label":"Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)","type":"EXPERIMENTAL"}],"summary":"The primary objective of this extension study is to assess the maintenance of efficacy of linzagolix administered orally once daily for up to an additional 6 months (for up to 12 months of treatment in total) in women who have already completed 6 months of linzagolix treatment at a dose of 75 mg alone or of 200 mg in combination with ABT (E2 1 mg / NETA 0.5 mg), in the management of moderate to severe endometriosis-associated pain (EAP) in women with surgically confirmed endometriosis.","primaryOutcome":{"measure":"Dysmenorrhea","timeFrame":"6-month extension study treatment period (from Month 6 to Month 12)","effectByArm":[{"arm":"LGX 75 mg","deltaMin":62,"sd":null},{"arm":"LGX 200 mg+ABT","deltaMin":101,"sd":null},{"arm":"Placebo/LGX 75 mg","deltaMin":32,"sd":null},{"arm":"Placebo/LGX 200 mg+ABT","deltaMin":43,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":47,"countries":["United States","Austria","Bulgaria","Czechia","France","Poland","Romania","Spain","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":119},"commonTop":["COVID-19","Headache","Hot flush","Anaemia","Vaginal haemorrhage"]}}